AARTI DRUGS LTD. - 524348 - Announcement under Regulation 30 (LODR)-Investor Presentation
Please find attached herewith Q3FY23 Results presentation of the Company for your records.27-01-2023
27-01-2023
AARTI DRUGS LTD. - 524348 - Interim Date- Record Date Wednesday, February 8, 2023
Please note that as per Regulation 42(1)(a) of the SEBI (LODR) Regulations, 2015, Wednesday, February 8, 2023 has been fixed as 'Record Date' for the purpose of payment of Interim Dividend.27-01-2023
AARTI DRUGS LTD. - 524348 - Corporate Action-Board approves Dividend
We wish to inform you that the Board of Directors of the Company at its Meeting held on Friday, January 27, 2023, has declared the Interim Dividend of Re. 1/- (Rupee One) (@10%) per Equity share of Rs. 10/- each for the financial year 2022-23.27-01-2023
AARTI DRUGS LTD. - 524348 - Board Meeting Outcome for Compliance Of Regulation 42(1)(A) And Regulation 43 Of The SEBI (LODR) Regulations, 2015.
We wish to inform you that the Board of Directors of the Company at its Meeting held on Friday, January 27, 2023, has declared the Interim Dividend of Re. 1/- (Rupee One) (@10%) per Equity share of Rs. 10/- each for the financial year 2022-2327-01-2023
AARTI DRUGS LTD. - 524348 - Audited Standalone And Consolidated Financial Results For The Quarter And Nine Months Ended December 31, 2022.
Audited Standalone and Consolidated Financial Results for the Quarter and Nine months ended December 31, 2022.27-01-2023
AARTI DRUGS LTD. - 524348 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
This is to inform you that Quarterly Conference Call for the Investors and Analysts has been scheduled on Monday, January 30, 2023 at 03:30 P.M. IST to discuss the Company's financial performance for the Quarter and nine months ended December 31, 2022.25-01-2023
AARTI DRUGS LTD. - 524348 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for issuance of Letter of Confirmation in lieu of Duplicate Share Certificate24-01-2023
AARTI DRUGS LTD. - 524348 - Board Meeting Intimation for Approval Of Financial Results And Consideration Of Interim Dividend
AARTI DRUGS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/01/2023 ,inter alia, to consider and approve - Audited Financial Results for the Quarter and Nine months ended December 31, 2022 - Interim dividend for the FY 2022-23, if any.20-01-2023
AARTI DRUGS LTD. - 524348 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of Loss of Share Certificate under Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201519-01-2023
AARTI DRUGS LTD. - 524348 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of Loss of Share Certificate under Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201513-01-2023